The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT-EHA CAR-T 2019 | Evaluating the efficacy of CAR T-cell therapies
Follow-up care for cancer patients is necessary to evaluate the effectiveness of the treatment they receive. Here, Arnon Nagler, MD, from Chaim Sheba Medical Center, Tel-Aviv, Israel, describes the numerous predictive factors that are currently being used to evaluate the response towards CAR T-cell therapy. This video was recorded at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).
